<DOC>
	<DOC>NCT00306215</DOC>
	<brief_summary>The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn's Disease.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key moderate to severe Crohn's Disease CDAI 250450 CRP &gt;7.5 signed written informed consent Key &gt; 100 cm of small bowel resected ileostomy, colostomy or rectal pouch diagnosis of ulcerative colitis or indeterminate colitis evidence of short bowel syndrome requiring enteral or parenteral supplementation or total parenteral nutrition hepatitis B, C or HIV infection history of infection requiring IV antibiotics serious or GI infection in the previous 12 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>multicenter</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>